Oruka Therapeutics’ long-acting plaque psoriasis candidate cleared the skin of 63.5% of patients in a phase 2a trial, leading ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible resultsSome results have been hidden because they may be inaccessible to you
Show inaccessible results